CA2736812A1 - A polysaccharide capsule enclosing a fatty acid oil-containing emulsion - Google Patents

A polysaccharide capsule enclosing a fatty acid oil-containing emulsion Download PDF

Info

Publication number
CA2736812A1
CA2736812A1 CA2736812A CA2736812A CA2736812A1 CA 2736812 A1 CA2736812 A1 CA 2736812A1 CA 2736812 A CA2736812 A CA 2736812A CA 2736812 A CA2736812 A CA 2736812A CA 2736812 A1 CA2736812 A1 CA 2736812A1
Authority
CA
Canada
Prior art keywords
fatty acid
weight
emulsion
capsule
oil mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2736812A
Other languages
English (en)
French (fr)
Inventor
Gunnar Berge
Svein Olaf Hustvedt
Thomas Andersen
Olav Gaseroed
Peder Oscar Andersen
Christian Klein Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
Pronova Biopharma Norge AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge AS filed Critical Pronova Biopharma Norge AS
Publication of CA2736812A1 publication Critical patent/CA2736812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
CA2736812A 2008-09-10 2009-09-10 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion Abandoned CA2736812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/207,824 2008-09-10
US12/207,824 US20100062057A1 (en) 2008-09-10 2008-09-10 Formulation
PCT/IB2009/006933 WO2010029433A1 (en) 2008-09-10 2009-09-10 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion

Publications (1)

Publication Number Publication Date
CA2736812A1 true CA2736812A1 (en) 2010-03-18

Family

ID=41799505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736812A Abandoned CA2736812A1 (en) 2008-09-10 2009-09-10 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion

Country Status (11)

Country Link
US (2) US20100062057A1 (enExample)
EP (1) EP2341901A4 (enExample)
JP (1) JP2012502090A (enExample)
KR (1) KR20110058881A (enExample)
CN (1) CN102209534A (enExample)
AU (1) AU2009290542A1 (enExample)
BR (1) BRPI0918429A2 (enExample)
CA (1) CA2736812A1 (enExample)
EA (1) EA201170433A1 (enExample)
MX (1) MX2011002640A (enExample)
WO (1) WO2010029433A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2979118T3 (es) 2009-03-09 2024-09-24 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un ácido graso libre, y procedimientos y usos de las mismas
BR112012005453B1 (pt) * 2009-09-10 2019-09-24 DuPont Nutrition USA, Inc. Cápsula sem costura, e, método para preparar uma cápsula de alginato sem costura
JP6116905B2 (ja) * 2009-10-23 2017-04-19 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 脂肪酸油混合物の被覆型カプセル剤および錠剤
WO2011051743A1 (en) 2009-10-30 2011-05-05 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
DE102010001179A1 (de) * 2010-01-25 2011-07-28 Technische Universität Dresden, 01069 Verwendung von Hydrogelen auf Basis guluronsäure- und/oder mannuronsäurehaltiger Polysaccharide zur Behandlung von Beschädigungen des Nervensystems, zur Förderung des Nervenwachstums, zur Behandlung von neurodegenerativen Erkrankungen und zur Kultivierung von Neuronen
GB201006204D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CA2706272C (en) 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
SG191383A1 (en) 2010-12-29 2013-08-30 Abbott Lab Nutritional products including monoglycerides and fatty acids
ITMI20111050A1 (it) 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
SMT201700470T1 (it) * 2011-06-15 2018-01-11 Stable Solutions Llc Applicazione terapeutica di olio di krill parenterale
US8895074B2 (en) * 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
TW201343203A (zh) * 2011-12-22 2013-11-01 Pronova Biopharma Norge As 含有ω－３脂肪酸之經明膠／藻酸鹽延緩釋放型膠囊，其製法及用途
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
WO2014074625A1 (en) 2012-02-21 2014-05-15 Allurion Technologies, Inc. Anatomically adapted ingestible delivery systems and methods
US10182932B2 (en) 2012-02-21 2019-01-22 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
ES2608629T3 (es) 2012-02-21 2017-04-12 Allurion Technologies, Inc. Dispositivos para el despliegue y la liberación de un implante temporal en el cuerpo
WO2013129168A1 (ja) * 2012-02-29 2013-09-06 日清オイリオグループ株式会社 カプセル食品およびカプセル含有油脂組成物
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2013148136A1 (en) 2012-03-30 2013-10-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
AU2013284464A1 (en) * 2012-06-29 2015-01-22 Amarin Pharmaceuticals Ireland Limited Methods of treating pediatric metabolic syndrome
GB201216385D0 (en) * 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
AU2015293628B2 (en) 2014-07-21 2019-06-20 Sevecom S.P.A. Powdered emulsion for animal feed
EP3236954B2 (en) * 2014-12-23 2024-09-04 DuPont Nutrition USA, Inc. Enteric film coating compositions, method of coating, and coated forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN107427462B (zh) * 2015-03-12 2023-08-29 杜邦营养美国有限公司 固态分散体
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
ES2607715B1 (es) * 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
KR101634314B1 (ko) * 2015-10-22 2016-06-30 한방약초힐링 농업회사법인주식회사 식물성 오메가-3 함유 기능성 미세분말 제조방법
CN108348407B (zh) * 2015-11-25 2021-03-12 麻沼株式会社 胶囊的制备方法
EP3755240B1 (en) 2018-02-26 2024-03-27 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
CA3091686A1 (en) 2018-03-15 2019-09-19 R.P. Scherer Technologies, Llc Enteric softgel capsules
CN108704588B (zh) * 2018-06-29 2020-10-09 广西壮族自治区林业科学研究院 一种微胶囊化酸性水溶液的制备方法
ES2974220T3 (es) 2018-07-06 2024-06-26 Allurion Tech Inc Sistema de válvula de control de fluido binaria
EP3886774A4 (en) 2018-12-13 2022-09-28 Allurion Technologies, Inc. ENHANCED FLUID DELIVERY SYSTEM
BR112021021448A2 (pt) * 2019-04-30 2021-12-21 Dsm Ip Assets Bv Sistema de distribuição para ácidos graxos poli-insaturados
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
US12246163B2 (en) 2023-04-12 2025-03-11 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
US12245962B2 (en) 2023-04-12 2025-03-11 Allurion Technologies, Inc. Balloon sealing and fill valve

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US3682654A (en) * 1970-03-13 1972-08-08 Gen Mills Inc Artificial flavored berries and process of preparing same
US4507327A (en) * 1983-05-23 1985-03-26 Q.P. Corporation Process for preparing edible products in the form of capsules
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS6121070A (ja) * 1984-07-11 1986-01-29 Q P Corp 魚卵様食品の製法
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3836138A1 (de) * 1987-10-28 1989-05-18 Gutec Gmbh Zur selektiven abtrennung von metallkationen aus waessrigen loesungen geeignetes teilchenfoermiges mittel, verfahren zu seiner herstellung und seine verwendung
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
EP0573978B1 (en) * 1992-06-12 1999-04-21 Kao Corporation Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules.
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JP3238350B2 (ja) * 1997-05-27 2001-12-10 三粧化研株式会社 可食性パール状カプセルおよびその製造法
WO1999022719A1 (fr) * 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
JP4761093B2 (ja) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
EP1129771B1 (de) * 2000-03-04 2005-12-21 Cognis IP Management GmbH Mikrokapseln
US7264824B1 (en) * 2000-04-13 2007-09-04 Meduna Arzneimittel Gmbh Oral dosage form
ATE305810T1 (de) * 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
AR039170A1 (es) * 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
NO20021592D0 (no) * 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
KR101250087B1 (ko) * 2002-06-24 2013-04-02 추가이 세이야쿠 가부시키가이샤 비구형 심리스 캡슐의 제조방법 및 제조장치
US7431986B2 (en) * 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040254357A1 (en) * 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
ITMI20031617A1 (it) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus Microcapsule a doppio strato di polisaccaridi utilizzabili

Also Published As

Publication number Publication date
BRPI0918429A2 (pt) 2015-11-24
JP2012502090A (ja) 2012-01-26
EA201170433A1 (ru) 2011-10-31
KR20110058881A (ko) 2011-06-01
CN102209534A (zh) 2011-10-05
WO2010029433A1 (en) 2010-03-18
US20100062057A1 (en) 2010-03-11
US20110262534A1 (en) 2011-10-27
AU2009290542A2 (en) 2011-03-31
AU2009290542A1 (en) 2010-03-18
EP2341901A4 (en) 2013-07-17
MX2011002640A (es) 2011-04-07
EP2341901A1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
US20110262534A1 (en) polysaccharide capsule enclosing a fatty acid oil-containing emulsion
US11523999B2 (en) Compositions comprising a fatty aged oil mixture and a free fatty acid, and methods and uses thereof
US9370493B2 (en) Coated capsules and tablets of a fatty acid oil mixture
JP2013508348A5 (enExample)
US9585896B2 (en) Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
WO2013072767A1 (en) Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150910